Opiant Pharmaceuticals, Inc.
OPNT · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $40,725 | $27,402 | $38,236 | $13,513 |
| % Growth | 48.6% | -28.3% | 183% | – |
| Cost of Goods Sold | $9,066 | $6,197 | $7,720 | $1,491 |
| Gross Profit | $31,659 | $21,205 | $30,516 | $12,022 |
| % Margin | 77.7% | 77.4% | 79.8% | 89% |
| R&D Expenses | $16,834 | $9,240 | $9,079 | $8,479 |
| G&A Expenses | $12,153 | $11,743 | $12,197 | $11,264 |
| SG&A Expenses | $16,729 | $16,429 | $12,809 | $11,478 |
| Sales & Mktg Exp. | $4,576 | $4,687 | $612 | $213,897 |
| Other Operating Expenses | -$7,060 | -$2,223 | -$2,283 | $13,256 |
| Operating Expenses | $26,502 | $23,446 | $19,605 | $33,212 |
| Operating Income | $5,156 | -$2,241 | $10,911 | -$21,190 |
| % Margin | 12.7% | -8.2% | 28.5% | -156.8% |
| Other Income/Exp. Net | -$2,123 | -$9 | $67 | $46,407 |
| Pre-Tax Income | $3,033 | -$2,287 | $11,416 | -$21,144 |
| Tax Expense | $24 | -$426 | -$177 | $51 |
| Net Income | $3,009 | -$1,861 | $11,593 | -$21,195 |
| % Margin | 7.4% | -6.8% | 30.3% | -156.8% |
| EPS | 0.68 | -0.44 | 2.88 | -7.1 |
| % Growth | 254.5% | -115.3% | 140.6% | – |
| EPS Diluted | 0.51 | -0.44 | 2.17 | -7.1 |
| Weighted Avg Shares Out | 4,456 | 4,250 | 4,018 | 2,985 |
| Weighted Avg Shares Out Dil | 5,920 | 4,250 | 5,342 | 2,985 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $94 | $438 | $0 |
| Interest Expense | $2,129 | $131 | $0 | $0 |
| Depreciation & Amortization | $662 | $608 | $238 | $3 |
| EBITDA | $5,829 | -$1,548 | $11,149 | -$21,141 |
| % Margin | 14.3% | -5.6% | 29.2% | -156.4% |